This clinical trial tests the effect of participating in a physical activity intervention in patients undergoing androgen deprivation therapy (ADT) for stage II-IV prostate cancer (PC). ADT leads to harmful changes in body composition and metabolic functioning that worsens fatigue, exercise intolerance, and increases future risk for cardiovascular disease (CVD). Men with PC who live in rural areas experience disparities in PC care and have worse outcomes than those living in urban settings. Exercise training is an effective non-pharmacological approach to treating both the side-effects of PC therapy and CVD. Information gathered from this study may help researchers determine whether participating in a behavioral exercise training program helps preserve exercise capability and quality of life, as well as lessening the side effects from ADT in patients with stage II-IV PC.
Additional locations may be listed on ClinicalTrials.gov for NCT06250751.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVE:
I. To iteratively refine a 12-week, behavioral exercise training (BET) intervention among 30 men currently undergoing ADT.
SECONDARY OBJECTIVE:
I. To determine the preliminary efficacy and fidelity of the proposed BET intervention among all 30 underserved PC patients by examining changes in activity levels, submaximal exercise capacity, physical function and adherence to the program.
OUTLINE:
Patients participate in the BET intervention for 12 weeks consisting of home-based exercise and behavioral counseling sessions to support adoption and maintenance of exercise and to troubleshoot any barriers. Behavioral counseling sessions occur twice per week (BIW) during weeks 1-2, once per week (QW) during weeks 3-8, and once every two weeks (Q2W) during weeks 9-12. Patients also wear ActivPAL and Actigraph devices for monitoring physical activity for 7-10-days.
After completion of study intervention, patients are followed up at 30 days.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationVCU Massey Comprehensive Cancer Center
Principal InvestigatorAlexander R Lucas